Exploring the Impact of Semaglutide on Cognitive Function and Anxiety-Related Behaviors in a Murine Model of Alzheimer’s Disease DOI Creative Commons
Ianis Kevyn Stefan Boboc,

Petrica-Daniel Dumitrelea,

Andreea-Daniela Meca

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(12), P. 2689 - 2689

Published: Nov. 25, 2024

Alzheimer's disease (AD), the most prevalent form of dementia, is characterized by progressive cognitive decline and behavioral disturbances, with an increasing incidence as global population ages. This study investigates effects semaglutide (SEM), a glucagon-like peptide-1 analog, on function anxiety-like behavior in transgenic murine model AD. 20 mice were randomly distributed into following groups ( Post-treatment, SEM significantly reduced blood glucose levels AD mice, aligning them those wild-type controls. Cognitive assessments indicated improvement investigation index for SEM-treated compared to receiving vehicle, suggesting benefits. Although did not enhance motor exploratory activities, it displayed potential anxiolytic effect, particularly evident combined anxiety index, notable differences observed before after treatment group. The findings this pilot suggest that may play dual role managing improving glycemic control potentially enhancing function. As landscape evolves, comprehensive approach utilizing could pave way innovative interventions targeting complex interplay metabolic dysfunctions challenging neurodegenerative disorder.

Language: Английский

GLP-1RA and SGLT2i Medications for Type 2 Diabetes and Alzheimer Disease and Related Dementias DOI
Huilin Tang, William T. Donahoo, Steven T. DeKosky

et al.

JAMA Neurology, Journal Year: 2025, Volume and Issue: unknown

Published: April 7, 2025

Importance The association between glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) risk of Alzheimer disease related dementias (ADRD) remains to be confirmed. Objective To assess the ADRD associated with GLP-1RAs SGLT2is in people type 2 diabetes (T2D). Design, Setting, Participants This target trial emulation study used electronic health record data from OneFlorida+ Clinical Research Consortium January 2014 June 2023. Patients were 50 years or older T2D no prior diagnosis antidementia treatment. Among 396 963 eligible patients T2D, 33 858 included GLP-1RA vs other glucose-lowering drug (GLD) cohort, 34 185 SGLT2i GLD 24 117 cohort. Exposures Initiation treatment a GLP-1RA, SGLT2i, second-line GLD. Main Outcomes Measures was identified using clinical codes. Hazard ratios (HRs) 95% CIs estimated Cox proportional hazard regression models inverse probability weighting (IPTW) adjust for potential confounders. Results cohort (mean age, 65 years; 53.1% female), 65.8 49.3% 63.8 51.7% female). In IPTW-weighted cohorts, incidence rate lower initiators compared (rate difference [RD], −2.26 per 1000 person-years [95% CI, −2.88 −1.64]), yielding an HR 0.67 (95% 0.47-0.96). had than (RD, −3.05 −3.68 −2.42]), 0.57 0.43-0.75). There SGLT2is, RD −0.09 −0.80 0.63) 0.97 0.72-1.32). Conclusion Relevance both statistically significantly decreased GLDs, observed drugs.

Language: Английский

Citations

2
Alzheimer’s Disease as Type 3 Diabetes: Understanding the Link and Implications DOI Open Access
Mateusz Kciuk, Weronika Kruczkowska, Julia Gałęziewska

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(22), P. 11955 - 11955

Published: Nov. 7, 2024

Alzheimer's disease (AD) and type 2 diabetes mellitus (T2DM) are two prevalent conditions that present considerable public health issue in aging populations worldwide. Recent research has proposed a novel conceptualization of AD as "type 3 diabetes", highlighting the critical roles insulin resistance impaired glucose metabolism pathogenesis disease. This article examines implications this association, exploring potential new avenues for treatment preventive strategies AD. Key evidence linking to emphasizes metabolic processes contribute neurodegeneration, including inflammation, oxidative stress, alterations signaling pathways. By framing within context, we can enhance our understanding its etiology, which turn may influence early diagnosis, plans, measures. Understanding manifestation opens up possibility employing therapeutic incorporate lifestyle modifications use antidiabetic medications mitigate cognitive decline. integrated approach improve patient outcomes deepen comprehension intricate relationship between neurodegenerative diseases disorders.

Language: Английский

Citations

13
Low-grade Chronic Inflammation: A Shared Mechanism for Chronic Diseases DOI
Mariana Cifuentes, Hugo Verdejo, Pablo Castro

et al.

Physiology, Journal Year: 2024, Volume and Issue: 40(1), P. 000 - 000

Published: July 30, 2024

Inflammation is an important physiological response of the organism to restore homeostasis upon pathogenic or damaging stimuli. However, persistence harmful trigger a deficient resolution process can evolve into state low-grade, chronic inflammation. This condition strongly associated with development several increasingly prevalent and serious conditions, such as obesity, cancer, cardiovascular diseases, elevating overall morbidity mortality worldwide. The current pandemic diseases underscores need address inflammation, its mechanisms, potential preventive measures limit widespread impact. present review discusses knowledge research gaps regarding association between low-grade inflammation focusing on digestive cancer. We examine art in selected aspects topic propose future directions approaches for field.

Language: Английский

Citations

10
IUPHAR review: Drug Repurposing in Schizophrenia – An Updated Review of Clinical Trials DOI Creative Commons
Jihan K. Zaki, Jakub Tomasik,

Sabine Bahn

et al.

Pharmacological Research, Journal Year: 2025, Volume and Issue: unknown, P. 107633 - 107633

Published: Jan. 1, 2025

There is an urgent need for mechanistically novel and more efficacious treatments schizophrenia, especially those targeting negative cognitive symptoms with a favorable side-effect profile. Drug repurposing-the process of identifying new therapeutic uses already approved compounds-offers promising approach to overcoming the lengthy, costly, high-risk traditional CNS drug discovery. This review aims update our previous findings on clinical repurposing pipeline in schizophrenia. We examined studies conducted between 2018 2024, 61 trials evaluating 40 unique repurposed candidates. These encompassed broad range pharmacological mechanisms, including immunomodulation, enhancement, hormonal, metabolic, neurotransmitter modulation. A notable development combination muscarinic modulators xanomeline, compound antipsychotic properties, trospium, included mitigate peripheral side effects, now by FDA as first decades fundamentally mechanism action. Moving beyond dopaminergic paradigm such highlight opportunities improve treatment-resistant alleviate adverse effects. Overall, evolving landscape illustrates significant shift rationale schizophrenia development, highlighting potential silico strategies, biomarker-based patient stratification, personalized that align underlying pathophysiological processes.

Language: Английский

Citations

1
Unlocking the Potential: Semaglutide’s Impact on Alzheimer’s and Parkinson’s Disease in Animal Models DOI Creative Commons
Andreea-Daniela Meca, Ianis Kevyn Stefan Boboc, Liliana Mititelu-Tarțău

et al.

Current Issues in Molecular Biology, Journal Year: 2024, Volume and Issue: 46(6), P. 5929 - 5949

Published: June 13, 2024

Semaglutide (SEM), a glucagon-like peptide-1 receptor agonist, has garnered increasing interest for its potential therapeutic effects in neurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson’s (PD). This review provides comprehensive description of SEM’s mechanism action preclinical studies these debilitating conditions. In animal models AD, SEM proved beneficial on multiple pathological hallmarks the disease. administration been associated with reductions amyloid-beta plaque deposition mitigation neuroinflammation. Moreover, treatment shown to ameliorate behavioral deficits related anxiety social interaction. SEM-treated animals exhibit improvements spatial learning memory retention tasks, evidenced by enhanced performance maze navigation tests novel object recognition assays. Similarly, PD, demonstrated promising neuroprotective through various mechanisms. These include modulation neuroinflammation, enhancement mitochondrial function, promotion neurogenesis. Additionally, improve motor function dopaminergic neuronal loss, offering disease-modifying strategies. Overall, accumulating evidence from suggests that holds promise approach AD PD. Further research is warranted elucidate underlying mechanisms translate findings into clinical applications devastating disorders.

Language: Английский

Citations

5
Echoes of Dormancy: Anomic Aphasia Unveils Neurocysticercosis Reactivation in a Patient on Semaglutide DOI Creative Commons

Marcos Osorio Borjas,

Robert J. Hernandez,

Angelo Lopez-Lacayo

et al.

NeuroSci, Journal Year: 2025, Volume and Issue: 6(2), P. 40 - 40

Published: May 5, 2025

Neurocysticercosis (NCC), a parasitic infection caused by Taenia solium larvae, remains leading cause of acquired epilepsy worldwide, particularly in regions with inadequate sanitation and healthcare access. We present case NCC reactivation 64-year-old female who developed anomic aphasia—a rare manifestation NCC—decades after her initial diagnosis. The patient’s clinical course was complicated potential trigger semaglutide, which potentially attenuated the protective inflammatory response maintained astrocytes microglia, to dormant cysts. Brain imaging confirmed localized cystic changes, treatment antiparasitic agents corticosteroids led marked improvement. This highlights complexity reactivation, highlighting interplay metabolic, immune, factors. It emphasizes need for vigilance managing patients infections investigating risks associated novel therapeutic like GLP-1 receptor agonists. Further research is essential unravel mechanisms linking metabolic modulation offering insights into prevention strategies.

Language: Английский

Citations

0
Liraglutide Inhibits Autophagy to Ameliorate Post-Cardiac Arrest Brain Injury and Ferroptosis in Rats DOI

Chengjun Xing,

Xin Fan,

Meiqiu Liu

et al.

Neurochemical Research, Journal Year: 2025, Volume and Issue: 50(3)

Published: May 11, 2025

Language: Английский

Citations

0
Can we target insulin signalling for cognition therapeutics? DOI
Simone Macrı̀, Giovanni Laviola

Expert Opinion on Therapeutic Targets, Journal Year: 2024, Volume and Issue: 28(9), P. 713 - 717

Published: Sept. 1, 2024

Language: Английский

Citations

1
Exploring the Impact of Semaglutide on Cognitive Function and Anxiety-Related Behaviors in a Murine Model of Alzheimer’s Disease DOI Creative Commons
Ianis Kevyn Stefan Boboc,

Petrica-Daniel Dumitrelea,

Andreea-Daniela Meca

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(12), P. 2689 - 2689

Published: Nov. 25, 2024

Alzheimer's disease (AD), the most prevalent form of dementia, is characterized by progressive cognitive decline and behavioral disturbances, with an increasing incidence as global population ages. This study investigates effects semaglutide (SEM), a glucagon-like peptide-1 analog, on function anxiety-like behavior in transgenic murine model AD. 20 mice were randomly distributed into following groups ( Post-treatment, SEM significantly reduced blood glucose levels AD mice, aligning them those wild-type controls. Cognitive assessments indicated improvement investigation index for SEM-treated compared to receiving vehicle, suggesting benefits. Although did not enhance motor exploratory activities, it displayed potential anxiolytic effect, particularly evident combined anxiety index, notable differences observed before after treatment group. The findings this pilot suggest that may play dual role managing improving glycemic control potentially enhancing function. As landscape evolves, comprehensive approach utilizing could pave way innovative interventions targeting complex interplay metabolic dysfunctions challenging neurodegenerative disorder.

Language: Английский

Citations

0